专访科济药业董事会主席李宗海:未来公司重点是实体瘤CAR-T和通用型CAR-T

每日经济新闻
20 Mar

3月18日,CAR-T(嵌合抗原受体T细胞免疫疗法)研发及生产企业科济药业-B(02171.HK)发布2024财年业绩报告。报告期内,公司共实现营业收入3942.50万元,净亏损7.98亿元,亏损同比扩大6.73%。亏损的主要来源在于高额的研发投入和非经常性亏损项目,尤其是因管线战略调整、更加专注于通用型CAR-T所带来的非流动资产减值亏损达1.89亿元。  目前,科济药业的营收主要来自赛恺泽(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10